For research and educational purposes only. Not medical advice.
Etelcalcetide Reference
Educational, not medical advice reference for Etelcalcetide: Hormonal, Bone; regulatory status, evidence posture, source review, and schedule notes. Also kno…
Reference summary
Etelcalcetide is a label-verified calcium-sensing receptor agonist with FDA Phase 3 evidence in secondary hyperparathyroidism in dialysis. pepSmart surfaces label-reference content only.
- Categories
- Hormonal, Bone
- Aliases
- Parsabiv, AMG 416, KAI-4169, Calcimimetic peptide
- Evidence posture
- human - Hypocalcemia is the principal label-level safety concern - reported associations include paresthesias, myalgias, muscle spasms, seizures, QT prolongation, and ventricular arrhythmias. Label also notes worsening heart failure, upper gastrointestinal bleeding, and adynamic bone risk if PTH is chronically suppressed. Clinician-administered IV-only; no consumer self-administration pathway exists.
- Regulatory status
- FDA-approved prescription medication (Parsabiv). Initial US approval 2017. Indicated for secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis. Calcium-sensing receptor agonist peptide; clinician-administered IV-only at the end of hemodialysis. Not indicated in chronic kidney disease patients who are not on hemodialysis. Prescription-only.
- Content review status
- label verified